News
In terms of drug class, immunosuppressants hold the largest market share, accounting for 42.10% in 2024. Their effectiveness ...
20h
Zacks Investment Research on MSNZoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseWall Street expects a year-over-year increase in earnings on higher revenues when Zoetis (ZTS) reports results for the ...
Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...
Animal health company Zoetis has partnered with the Beyond Blue mental health charity since 2016, donating more than $900,000 ...
In Scotland, a Zoetis UK survey of pet owners revealed similar concerns about skin-related discomfort in pets. Around 71% of owners reported noticing their pets licking excessively, 65% had observed ...
After Advent's Felix Pharma buyout, another deal is brewing in the vet medicine segment. Multiples and other investors of ...
StockStory.org on MSN5d
Zoetis (ZTS): Buy, Sell, or Hold Post Q1 Earnings?Over the last six months, Zoetis’s shares have sunk to $153.39, producing a disappointing 11.4% loss - a stark contrast to ...
Breed Explorer offers veterinarian-approved, science-backed insights to help current and prospective pet owners make informed decisions.
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” second quarter 2025 investor ...
The stock's rise snapped a five-day losing streak.
A stock that has been tumbling in a short period of time can create a good buying opportunity for investors. If the drop in share price is due to a possible overreaction to a recent news event or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results